EP1945669A1 - Chimeric antibodies with new world primate regions - Google Patents
Chimeric antibodies with new world primate regionsInfo
- Publication number
- EP1945669A1 EP1945669A1 EP06774813A EP06774813A EP1945669A1 EP 1945669 A1 EP1945669 A1 EP 1945669A1 EP 06774813 A EP06774813 A EP 06774813A EP 06774813 A EP06774813 A EP 06774813A EP 1945669 A1 EP1945669 A1 EP 1945669A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- binding portion
- antibody
- chimeric antibody
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000288906 Primates Species 0.000 title claims abstract description 71
- 239000000427 antigen Substances 0.000 claims abstract description 149
- 108091007433 antigens Proteins 0.000 claims abstract description 149
- 102000036639 antigens Human genes 0.000 claims abstract description 149
- 230000027455 binding Effects 0.000 claims abstract description 132
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 84
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 208000035475 disorder Diseases 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 37
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims description 32
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 18
- 241000282412 Homo Species 0.000 claims description 17
- 241001515942 marmosets Species 0.000 claims description 16
- 102000005962 receptors Human genes 0.000 claims description 16
- 108020003175 receptors Proteins 0.000 claims description 16
- -1 EGF-R Proteins 0.000 claims description 13
- 230000005847 immunogenicity Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003053 toxin Substances 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 108700012359 toxins Proteins 0.000 claims description 9
- 241000282709 Aotus trivirgatus Species 0.000 claims description 8
- 102000003886 Glycoproteins Human genes 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 8
- 208000015114 central nervous system disease Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229960005156 digoxin Drugs 0.000 claims description 5
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 241001062548 Alouatta guariba Species 0.000 claims description 4
- 241000282672 Ateles sp. Species 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 101150013553 CD40 gene Chemical class 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 241000282688 Callicebus Species 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000994375 Homo sapiens Integrin alpha-4 Chemical class 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Chemical class 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Chemical class 0.000 claims description 4
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101000622137 Homo sapiens P-selectin Proteins 0.000 claims description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Chemical class 0.000 claims description 4
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 4
- 241000282675 Lagothrix Species 0.000 claims description 4
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102100023472 P-selectin Human genes 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 241000282695 Saimiri Species 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 108010013985 adhesion receptor Proteins 0.000 claims description 4
- 102000019997 adhesion receptor Human genes 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000000179 crotalid venom Substances 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 102100032937 CD40 ligand Human genes 0.000 claims description 3
- 102100029761 Cadherin-5 Human genes 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 claims description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 3
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 3
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 claims description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 3
- 102000043131 MHC class II family Human genes 0.000 claims description 3
- 108091054438 MHC class II family Proteins 0.000 claims description 3
- 108010080192 Purinergic Receptors Proteins 0.000 claims description 3
- 102000000033 Purinergic Receptors Human genes 0.000 claims description 3
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 3
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 3
- 108091008605 VEGF receptors Proteins 0.000 claims description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 102000054751 human RUNX1T1 Human genes 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- JFINOWIINSTUNY-UHFFFAOYSA-N pyrrolidin-3-ylmethanesulfonamide Chemical compound NS(=O)(=O)CC1CCNC1 JFINOWIINSTUNY-UHFFFAOYSA-N 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 3
- 102100022133 Complement C3 Human genes 0.000 claims 2
- 102100031506 Complement C5 Human genes 0.000 claims 2
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims 2
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims 2
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 101100504181 Arabidopsis thaliana GCS1 gene Chemical class 0.000 claims 1
- 241001515796 Cebinae Species 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 claims 1
- 101710123661 Venom allergen 5 Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- 108060003951 Immunoglobulin Proteins 0.000 description 18
- 102000018358 immunoglobulin Human genes 0.000 description 18
- 229920000642 polymer Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 239000012634 fragment Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 8
- 101100077710 Rattus norvegicus Mog gene Proteins 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 230000009824 affinity maturation Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000002254 cytotoxic agent Substances 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000057041 human TNF Human genes 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002773 nucleotide Chemical group 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 3
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- MOAVUYWYFFCBNM-PUGKRICDSA-N digoxin(1-) Chemical compound C[C@H]([C@H]([C@H](C1)O)O)O[C@H]1O[C@H]([C@@H](C)O[C@H](C1)O[C@H]([C@@H](C)O[C@H](C2)O[C@@H](CC3)C[C@@H](CC4)[C@@]3(C)[C@@H](C[C@H]([C@]3(C)[C@H](CC5)C([CH-]O6)=CC6=O)O)[C@@H]4[C@]35O)[C@H]2O)[C@H]1O MOAVUYWYFFCBNM-PUGKRICDSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 241000288950 Callithrix jacchus Species 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000282513 Cebidae Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102400000269 Amyloid protein A Human genes 0.000 description 1
- 101710144835 Amyloid protein A Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241001502973 Aotus nancymaae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 101000780591 Homo sapiens AFG3-like protein 2 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000629361 Homo sapiens Paraplegin Proteins 0.000 description 1
- 101000666340 Homo sapiens Tenascin Proteins 0.000 description 1
- 101000626125 Homo sapiens Tetranectin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150088952 IGF1 gene Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Chemical group 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004378 Melanocortin Receptors Human genes 0.000 description 1
- 108090000950 Melanocortin Receptors Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 231100000757 Microbial toxin Toxicity 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000054037 human AFG3L2 Human genes 0.000 description 1
- 102000055335 human SPG7 Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920001427 mPEG Polymers 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002859 polyalkenylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000024834 positive regulation of antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Definitions
- the present, invention relates to a chimeric antibody or antigen-binding portion thereof, wherein the antigen binding portion comprises at least two complementarity determining region (CDR) sequences and at least three framework regions, wherein at least one CDR is a New World primate CDR, and to the use of the antibody or antigen -binding portion thereof in treating diseases or disorders.
- CDR complementarity determining region
- Antibodies play an important role in the immune system of a mammal. They are produced by plasma cells which have developed from precursor B cells. Antibodies consist ⁇ f two identical light polypeptide chains and two identical heavy polypeptide chains which are joined by disulfide bridges. The light chains are referred to as either kappa or lambda light chains and the heavy chains as gamma, mu, delta, alpha or cpsilon. Each chain consists of a constant and variable region. The variable region gives the antibody its specificity. Within each variable region are regions of hypervari ability or complementarity determining regions (CDRs) which are flanked by more conserved regions referred to as framework regions. Within each variable region arc three CDRs and four framework regions.
- CDRs complementarity determining regions
- Antibodies are bifunctional molecules, the N-terminai variable segments from the heavy and light chains associate together in a specific manner to generate a three-dimensional structure with affinity for a particular epitope on the surface of an antigen.
- the constant region segments are responsible for prolonged serum half-life and the effector functions of the antibody and relate to complement binding, stimulation of phagocytosis, antibody- dependent cellular cytotoxicity and triggering of granulocyte granule release.
- hybridoma technology has facilitated the production of monoclonal antibodies of a particular specificity.
- hybi ⁇ domas are murine hybridor ⁇ as.
- Human/mouse chimeric antibodies have been created in which antibody variable region sequences from the mouse genome are combined with antibody constant region sequences from the human genome.
- the chimeric antibodies exhibit the binding characteristics of the parental mouse antibody, and the effector functions associated with the human constant region.
- the antibodies are produced by expression in a host cell, including for example Chinese Hamster Ovary (CHO), NSO myeloma cells, COS cells and SP2 cells.
- CHO Chinese Hamster Ovary
- NSO myeloma cells CHO
- COS cells COS cells
- SP2 cells a host cell
- Such chimeric antibodies have been used in human therapy, however antibodies to these chimeric antibodies have been produced by the human recipient.
- Such anti-chimcric antibodies are detrimental io continued therapy with chimeric antibodies.
- human monoclonal antibodies are expected to be aii improvement over mouse monoclonal antibodies for in vivo human therapy. From work done with antibodies from Old World primates (rhesus monkeys and chimpanzees) it has been postulated that these non-human primate antibodies will be tolerated in humans because they arc structurally similar to human antibodies (Ehrlich PH el al., Human and primate monoclonal antibodies for in vivo therapy. Clin Chem. 34:9 pg 168J- 1688 (1988)). Furthermore, because human antibodies are non-immunogenic in Rhesus monkeys (Ehrich PH et al.. Rhesus monkey responses to multiple injections of human monoclonal antibodies.
- Hybridoma 1987; 6:15.1-60 it is likely that the converse is also applicable and primate antibodies will be non-immunogenic in humans.
- These monoclonal antibodies are secreted by hybr ⁇ domas constructed by fusing lymphocytes to a human x. mouse heteromyeloma.
- EP 0 605442 discloses chimeric antibodies which bind human antigens. These antibodies comprise the whole variable region from an Old World monkey and the constant region of " a human or chimpanzee antibody.
- One of the advantages suggested in this reference for these constructs is the ability to raise antibodies in Old World monkeys to human antigens which arc less immunogenic in humans compared with antibodies raised in a mouse host.
- New World primates comprise at least 53 species commonly divided into two families, the CulUthricidae and Cebidae.
- the Callilhricidae eonsist of marmosets and tainarins.
- the Cebidae includes the squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, sakis, night or owl monkey and the howler monkey.
- Evolulionarily distant primates such as New World primates, are not only sufficiently different from humans to allow antibodies against human antigens to be generated, but are sufficiently similar to humans to have antibodies similar to human antibodies so that the host does not generate an anti-antibody immune response when such primatc-derived antibodies arc introduced into a human.
- Domain antibodies are functional binding units which can be created using antibody frameworks and correspond to the variable regions of either the heavy (VH) or light (V L ) chains of antibodies. Domain antibodies have a molecular weight of approximately 13 kDa, or less than one tenth the size of a full antibody.
- Immunoglobulin light chains are referred to as either kappa or lambda tight chains and the heavy chains as gamma, mu, delta, alpha or epsilon.
- the variable region gives the antibody its specificity, Within each variable region are regions of hypervari ability, otherwise known as complementarity determining regions (CDRs) which are flanked by more conserved regions referred to as framework regions. Within each light and heavy chain variable region are three CDRs and four framework regions.
- domain antibodies are well expressed in bacterial, yeast and mammalian systems. Their small size allows for higher molar quantities per gram of product, thus providing a significant increase in potency.
- domain antibodies can be used as a building block to create therapeutic products such as multiple targeting domain antibodies in which a construct containing two or more variable domains bind to two or more therapeutic targets, or domain antibodies targeted for pulmonary or oral administration.
- the present invention provides a chimeric antibody or an antigen-binding portion thereof, wherein the antigen-binding portion comprises at least two complementarity determining regions (C-DR) and at least three framework regions, wherein at least one CDR is a New World p ⁇ imate CDR.
- C-DR complementarity determining regions
- the present invention provides a method of producing a chimeric antibody ⁇ r an antigen-binding portion thereof, the method comprising deleting a CDR from a human antibody variable region comprising id least two CDRs and at least three framework regions and replacing it with a New World primate CDR predicted to he of low immunogenic ity to produce a chimeric variable region,
- the method further comprises the step of recovering the chimeric variable region.
- the present invention provides a chimeric antibody or an antigen- binding portion thereof produced according to the method of the present invention.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of tine antibody or antigen-binding portion thereof according to the present invention, together with a pharmaceutically acceptable excipitsnt or diluent.
- the invention provides for die use of an antibody or antigen-binding portion thereof of the present invention in a diagnostic application for detecting an antigen associated with a particular disease or disorder.
- the present invention provides a method for treating a disease or disorder characterised by human TNF- ⁇ activity in a human subject, comprising administering to the subject in need thereof an effective amount of a chimeric antibody as described herein, or a pharmaceutical composition thereof in which the antibody or antigen-binding portion thereof binds TNF- ⁇ .
- FIGURES figure 1 demonstrates the binding of AB 138 to rat MOG present in rat spinal cord lysatc (lane 2) and not to CHOKISV lysate (lane 3).
- J.ane 1 contains molecular weight markers.
- Figure 2 demonstrates the lack of non-specific binding of an OMl-TTJFa monoclonal antibody to the same sample of rat MOG present in rat spinal cord lysate ⁇ lunts 2) and CHC)KlSV lysalc (lane 3).
- Lane I contains molecular weight markers.
- Figure 3 shows the acceptor domain antibody amino acid and nucleotide sequence (both strands).
- CDR2 residues are indicated in underline.
- Figure 4 is a sequence alignment of the domain antibody acceptor sequence with a panel of New World primate derived immunoglobulin sequences performed using AlignX (Vector NTJ, Invitr ⁇ gen, Australia). The CDR2 is highlighted in bold text. DETAILED DESCRIPTION OF THE INVENTION
- the present invention provides a chimeric antibody or an antigen-binding portion thereof, wherein the antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR. It is preferred that the antigen binding portion comprises three CDRs and four framework regions. It is also preferred that the antigen-binding portion comprises at least one, and preferably two human CDRs.
- CDR complementarity determining regions
- the chimeric antibody or antigen-bmdmg portion thereof comprises one New World primate CDR.
- the chimeric antibody or antigen-binding portion thereof comprises two New World primate CDRs.
- CDR2 of the antibody or antigen-binding portion is a New World primate CDR.
- the at least one New World primate CDR is not from a sequence that binds a target antigen.
- the framework regions are human sequences. Framework regions that arc human sequences include sequences derived from human framework regions, or synthetic sequences based on human framework regions.
- sequence of the antigen hinding portion may be further subject to affinity maturation in order to improve its antigen binding characteristics such as antigen binding or potency.
- An increase in binding is demonstrated by a decrease in K D (K aff /k nn ) for the antibody or antigen binding portion thereof.
- ⁇ n increase in potency is demonstrated in biological assays.
- assays thaL can be used to measure the potency of the antibody or antigen-binding portion thereof include the TNF ⁇ -induced L929 cytotoxicity neutralisation assay, IL-12-induced human PH ⁇ -activaled peripheral blood mononuclear cell (PBMC) proliferation assay, and RANKL mediated osteoclast differentiation of mouse splcnocyles (Stem, Proc. Natl. Acad. Sci. USA 87:6808 - 6812 (1990); Kong, Y-Y. et a Nature 397:315 - 323 (1990); Matthews, N. and ML. Neale in Lymphokines and Interferons, a Practical Approach, 1987, MJ. Clemens, A.G. Morris and AJ.H. Gearing, cds., JRL Press, p. 22J)
- At least one framework region is modified to increase binding and/or to reduce predicted immunogcnicity in humans
- At least one CDR sequence is modified to increase binding or potency and or to reduce predicted immunogenicity in humans. It is preferred that where at least one CDR sequence which is modified it is not the New World primate CDR.
- At least one framework region is modi Tied, in addition to at least one CDR sequence, to increase binding and or to reduce predicted immunogenicity in humans. It is preferred that the at the least one CDR sequence which is modified it is not a New World primate CDR sequence.
- the antigen-binding portion is a domain antibody.
- the domain antibody may be multirncrised, as for example, hctero- or.homodimers (e.g., V H / V H , V L / V L or V H /VL), netero- or homolrimcrs (e.g., V II / V H / V H , V L / V L / V L , V H / V II / V L or V H / V L / V L ), hetcro- or homotetramers (e.g., V II /V H / V H / V II , V L / V L / V L / V L V H /V II /V H ,V L , V II / V H / V L / V L or V H /V L /V L /V L ), or higher order hetero- or homomultimers.
- hctero- or.homodimers e.g., V H / V H , V
- the invention provides a domain antibody wherein the domain antibody is linked, to at least one further domain antibody.
- Each domain antibody may bind to the same or different antigens.
- the domain antibody multimers may further comprise o ⁇ c or more domain antibodies which are linked and wherein each domain antibody binds to a different antigen, multi- specific Iigands including so-called "dual-specific ljgands".
- the dual specific Kenya may comprise a pair of V 11 domains or a pair of V L domains.
- dual-speci fie Iigands are described in WO 2004/003019 (PCT/GB2003/002804) in the name of Domanlis Ltd incorporated by reference herein in its entirety.
- the antibody or antigen-binding portion further comprises a human or non- human primate constant region sequence.
- non-human primates include, but are not limited to, chimpanzees, ⁇ rang ⁇ atangs and baboons.
- the present invention also provides a method of producing a chimeric antibody or an antigen -binding portion thereof, the method comprising deleting a CDR from a human antibody variable region comprising at least two CDRs and at least three framework regions and replacing it with a New World primate CDR predicted to be of low immunogcnicity to produce a chimeric variable region. Jn a related aspect the method further comprises the step of recovering the chimeric variable region.
- the selected New World prunate CDR is CDR2. It is preferred that the CDR2 sequence is selected from KVSNR ⁇ S, RVSNRAS, KVSTRGP, ⁇ ASKR ⁇ S, TSSNLQA, DASSLQP and YASFLQG. Particularly preferred sequences are KVSNRAS, A ⁇ SNRAS, TSSNLQ ⁇ and KVSTRGP due to their predicted lower immunogemcity.
- the method further comprises modifying the sequence of the chimeric variable region to increase binding and/or to decrease immuraogenicity in humans. It is preferred that the New World primate CDR sequence is not modified. Where two or more New World primate CDR sequences arc present then it is preferred that at least one New World primate CDR. is not modified.
- At least one framework region is modified in addition to at least one CDR sequence, to increase binding and or to reduce predicted immunogemcity in humans. It is preferred that the at the least one CDR sequence which is modified it is not a New World primate CDR. scquence.Thc present invention also provides a chimeric antibody or an antigen-binding portion thereof produced by the method of the present invention.
- the term "antibody” as used herein, is intended to refer to immunoglobulin molecules comprised ot four polypeptide chains, two heavy (H) chains and two light (Iy) chains interconnected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (HCVR or Vn) and a heavy chain constant region.
- the heavy chain constant region comprises three domains, C H I, C H 2 and Cn3>
- Each light chain is comprised of a light chain variable region (LCVR or V L ) and a light chain constant region.
- the light chain constant region is comprised of one domain, C L .
- the V H and V L regions can be further subdivided into regions of hypcrvariabilily, termed complementarity determining regions (CDR), interspersed with regions that arc more conserved, termed framework regions (FR).
- Each VH and V L i.s composed of three CDRs and four FRs, arranged from ammo-terminus to carboxy-tcrminutJ in the following order: FR 1 , CDRl, FR2, CDR2, FR3, CDR3, FR4,
- antigen-binding portion of an antibody refers to one or more components or derivatives of an immunoglobulin thai exhibit the ability to bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full length antibody.
- E ⁇ ampl ⁇ s of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V L , V H , C L and C H 1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V H and C H 1 domains; (iv) a Fv fragment consisting of the V t , and VH domains of a single arm of an antibody; (v) a dAb fragment (Ward et al, 1989, Nature 341 :544-54G) which consists of a single V H domain, or a V L domain (van don Beuken T et al, 2(X)I, J.
- a Fab fragment a monovalent fragment consisting of the V L , V H , C L and C H
- single chain Fvs are also intended to be encompassed within the term "antigen-binding portion" of an anti body.
- Other forms of single chain Fvs and related molecules such as diabodies or triabodies are also encompassed, Diabodies arc bivalent antibodies in which V H and V L domains arc expressed on a single polypeptide chain, buL using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., JJolliger, P., et al. r 1993, Proc. NaU. ⁇ cad. Sci.
- the domain antibody comprises a human framework regions and at letust one New World primate CJDRs, more preferably marmoset CDRs.
- the New World primate is selected from the group consisting of marmosets, lamatins, squirrel monkey, titi monkey, spider monkey, woolly monkey, capuchin, uakaris, saTds. night or owl monkey and the howler monkey. More preferably, the New Wortd primate is a marmoset.
- the antibody or antigen-binding portion thereof according to the present invention has predicted low immunogenic] ty in a human host.
- low immunogenioily il is meant that the antibody docs not raise an antibody response in at. least the majority of individuals receiving the antibody of sufficient magnitude to reduce the effectiveness of continued administration of the antibody for a sufficient time to achieve therapeutic efficacy.
- the level of immunogenicity in humans may predicted using the MHC class II binding 0 prediction program Propred (http://www.imtech.res.in/raghava/propred) using a 1% threshold value analysis of all alleles.
- Other programs which may bo used include:
- Low immunogenicity molecules will contain no or low numbers of peptides predicted to 5 bind to MlJC class Il alleles that are highly expressed in the target population (Flower DR, Doytchinova IA. (2004) Immunoinformatics and the prediction of immunogenicity, Drug Discov Today, 9(2): 82-90).
- Reduced immunogenicity molecules will contain no or a reduced numbers of peptides predicted to bind to MHC class Il alleles that are highly expressed in the target population, 0 relative to the starting donor molecule.
- Functional analysis of MHC class ⁇ I binding can be performed by generating overlapping peptides corresponding to lhc protein of interest and testing these for their ability to evoke T cell activation (T ce)! proliferation assay) or displace a reporter peptide, a known Ml IC class l!-binding peptide (Hammer J el at., 1994, J. Kxp. Med., 180:2353).
- the present invention is further based on a method for amplification of New World primate immunoglobulin genes, for example by polymerase chain reaction (PCR) from nucleic acid extracted from New World primate lymphocytes using primers specific for heavy and light chain variable region gene families.
- PCR polymerase chain reaction
- the amplified variable region is then cloned into an expression vector containing a human or primate constant region gene for the production of New World primate chimeric recombinant antibody.
- Standard recombinant DNA methodologies are used to obtain antibody heavy and light chain genes, incorporate these genes into recombinant expression vectors and introduce the vectors into host cells, such as those described in Sambrook, Krilsch and Maniotis (eds), Molecular Cloning: a laboratory manual, second edition, Cold Spring Harbor, N.Y (1989). Suitable expression vectors will be familiar to those skilled in the art.
- the New World pi imalc lymphocytes producing the immunoglobulins are typically immortalised by fusion with a myeloma cell line to generate a hybridoma.
- Preferred mammalian host cells for expressing the recombinant antibodies of the invention include Chinese I lamster Ovary (CHO), NSO myeloma cells, COS cells and SP2 cells.
- CHO Chinese I lamster Ovary
- NSO myeloma cells include Chinese I lamster Ovary (CHO), NSO myeloma cells, COS cells and SP2 cells.
- the present invention also contemplates the use of non-mammalian expression systems such as those which arc plant or prokaryotic (bacterial) derived. Such expression systems would be familiar to persons skilled in the art.
- the repertoire of Vn, V L and constant region domains can be a naturally occurring repertoire of immunoglobulin sequences or a synthetic repertoire.
- a nanirally occurring repertoire is one prepared, for example, from immunoglobulin expressing cells harvested from one or more primates. Such repertoires can be naive ie. prepared from newborn immunoglobulin expressing cells, or rearranged ie. prepared from, for example, adult primate B cells. If desired, clones identified from a natural repertoire, or any repertoire that bind the target antigen are then subject to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
- Synthetic repertoires of immunoglobulin variable domains are prepared by artificially introducing diversity into a cloned variable domain.
- affinity maturation techniques will be familiar to persons skilled in lhe art (Irving R. A. et ai (2001) Ribosorne display and affinity maturation: from antibodies Io single V-domains and steps towards cancer therapeutics, Journal of Immunological Methods, 248: 31-45).
- variable region, or a CDR thereof, of a New World primate antibody gene may be cloned by providing nucleic acid eg. cDN ⁇ , providing a primer complementary to the cDN A sequence encoding a 5' leader sequence of an antibody gene, contacting that cDNA and the primer to form a hybrid complex and amplifying the cDNA to produce nucleic acid encoding the variable region (or CDR region) of the New World primate antibody gene.
- non-New World primate variable region sequence may be used as an acceptor for grafting New World primate sequences, in particular, CDR sequences using standard recombinant techniques.
- CDR sequences using standard recombinant techniques.
- US Patent No. 5,585,089 describes methods for creating low immuiiogenicity chimeric antibodies that retain the high affinity of the non-human parent antibody and contain one or more CDRs from a donor immunoglobulin and a framework region from a human immunoglobulin.
- 20030039649 describes a humanisation method for creating low immiinogenicity chimeric antibodies containing CDR sequences from a non-human antibody and framework sequences of human antibodies based on using canonical CDR structure types of the non-human antibody in comparison to germline canonical CDR structure types of human antibodies as the basis for selecting the appropriate human framework sequences for a humanised antibody. Accordingly, these principles can be applied to the grafting of one Or more New World primate CDRs into a -non-New World primate acceptor variable region.
- the CDR sequences may be obtained from the genomic UNA isolated from an antibody, or from sequences present in a database e.g. The National Centre for Biotechnology Information protein and nucleotide databases, The Kabat Database of Sequences of Proteins of Immunological Interest
- the CDR sequence may be a genomic DNA or a cDNA.
- Methods for grafting a replacement CDR(s) into an acceptor variable sequence will be familiar to persons skilled in the an of the present invention.
- the CDRs will be grafted into acceptor variable region sequences for each of a variable light chain and a variable heavy chain or a sitiglc chain in the case of a domain antibody.
- the preferred method of the present invention involves replacement of either CDRl or, more preferably, CDR2 in a variable region sequence via primer directed mutagenesis.
- the method consists of annealing a synthetic oligonucleotide encoding a desired mutation to a target region where it servea as a primer for initiation of DNA synthesis in vitr ⁇ , extending the oligonucleotide by a DN ⁇ polymerase io generate a double-stranded I ) NA that carries the desired mutation, and ligating and cloning the sequence inlo an appropriate expression vector (Sambroolc, Joseph; and David W. Russell (2001). Molecular Cloning: A Laboratory Manual, 3rd cd., Cold Spring Harbor, N. Y.: Cold Spring Harbor Laboratory Press)..
- an antibody or antigen-binding portion thereof may be part of a larger immunoadhesio ⁇ molecule, formed by covalent or noncovalcnt association of the antibody ⁇ or antibody portion with one or more other proteins or peptides.
- immunoadhesio ⁇ molecule formed by covalent or noncovalcnt association of the antibody ⁇ or antibody portion with one or more other proteins or peptides.
- irnmunoadhesion molecules include use of the streplavidin core region to make a tctrameric seFv molecule (Kipriyanov, S. M., et al.
- the constant region sequence (Fe portion) is preferably obtained from a human or non- human primate immunoglobulin sequence.
- the primate sequence may be a New World primate or an Old World primate sequence. Suitable Old World primates include chimpanzee, or other hominid ape eg. gorilla or orang utan, which because of their close phylogenetic proximity to humans, share a high degree of homology with the human constant region sequence. Sequences which encode for human or primate constant regions are available from databases including e.g. 'Che National Centre for Biotechnology Information protein and nucleotide databases, The Kabat Database of " Sequences of Proteins of Immunological Interest.
- the antibody or antigen-binding portion according to the invention is capable of binding to a human or non-human antigen.
- the antigen to which the chimeric antibody or antigen-binding portion thereof binds is peptide, protein, carbohydrate, glycoprotein, lipid or glycolipid in nature, selected from a tumour-associated antigen including carcinoembryonic antigen, EpCAM, Lewis-Y, I-ewis-Y/b, PMSA, CD20, CD30, CD33, CD38, CD52, CD154, EGF-R, Her-2, TRAIL and VEGF receptors, an antigen involved in an immune or inflammatory disease or disorder including CD3, CD4, CD25, CD40, CD49d, MHC class I 7 MHC.: class II, GM- CSF, intcrfcron- ⁇ .
- IL-I IL-12, IL-13, IL-23, TNF- ⁇ , and IgE
- an antigen expressed on a host cell including glycoprotein Ub/AIIa, P-glycoprotcin, purinergjc receptors and adhesion receptors including CDlIa, CDl Ib, CDl Ic, CD18, CD56, CD58, CD62 or CD144, an antigen comprising a cytokine, chemokinc, gi'owth factor or other soluble physiological modulator or a receptor thereof including eotaxi ⁇ , 11 ⁇ 6, IL-8, TGF-p 1 , C3ii, C5n, VEGF, NGF and their receptors, an antigen involved in central nervous system diseases or disorders including ⁇ -amyloid and prions, an antigen of non-human origin such as microbial, nanobial or viral antigens or toxins including respiratory sync y tial vims protein F, anthrax toxin, rattle snake venom and
- the antigen is TNF ⁇ , preferably human TNFo.
- the chimeric antibody or antigen-binding portion thereof may bind a non-human antigen
- the non-human antigen is selected from the group consisting of respiratory syncytial virus F protein, cytomegalovirus, snake venoms and digoxin.
- the term "binds to” as used herein, is intended to refer to the binding of an antigen by an immunoglobulin variable region of an antibody with a dissociation constant (K ⁇ ) of l ⁇ lv ⁇ or lower as measured by surface plasmon resonance analysis using, for example a EI ⁇ eorcTM surface plasmon resonance system and BI ⁇ corcTM kinetic evaluation software (eg. version 2.1).
- the affinity or dissociation constant (Ku) for a specific binding interaction is preferably about 500 nM to about 50 pM, more preferably about 500 nM or lower, more preferably about 300 nM or lower and preferably at least about 300 nM to about 50 pM, about 200 nM to about 50 pM, and more preferably at least about 100 nM to about 50 pM, about 75 nM lo about 50 pM, about 10 nM to about 50 pM.
- the antibodies of the present invention are advantageous in human therapy because the likelihood of induction of a human anti-antibody response will be reduced.
- Recombinant antibodies produced according to the invention that hind a target antigen can be identified and isolated by screening a combinatorial immunoglobulin library (eg a phage display library) to isolate library members that exhibit the desired binding specificity and l ⁇ mctional behaviour.
- a combinatorial immunoglobulin library eg a phage display library
- the phage display technique has bcen described extensively in lhe art and examples of methods and compounds for generating and screening such libraries and affinity maturing the products of them can be found in, for example, Barbus et al. (1991) PNAS 88:7978-7982: Clarkson et al. (1991) Nature 352:624:628; Dower ct al. PCT. 91/17271 , U.S. Patent No. 5,427,908, U.S. Patent N ⁇ . 5,580,717 and EP 527,839; Fuchs et a!. (1991) Bio/Technology 9:1370-1372; Garrad et al.
- Recombinant libraries expressing the antibodies of the invention can be expressed on the surface of microorganisms eg. yeast or bacteria (sec PCT publications WO99/36569 and 98/49286),
- the Selected Lymphocyte Antibody Method or SLAM as it is referred to in the state of the art, is another means of generating high affinity antibodies rapidly. Unlike phage display approaches all antibodies are fully divalent.
- New World primates arc immunised with a human antigen eg. a TNFo: polypeptide. Following immunisation cells are removed and selectively proliferated in individual micro wells. Supematants arc removed from wells and tested for both binding and function.
- Gene sequences can be recovered for subsequent manipulations eg, humanisaliofl, Fab fragment, scFv or domain antibody generation.
- SLAM derivation of the ligand of the invention by SLAM and its derivatives (Babcook, J.S. et al 1996, Proc. Natl. Acad. Sci, US ⁇ 93; 7843-7848, US Patent 5,627,052 and PCT publication WO92/0255t).
- Adaptations of SLAM such as the use of alternatives to testing supernatants s ⁇ cli as panning, also lie within the scope of this invention.
- JLti one expression system the recombinant pepfide/protein library is displayed on ribosomes (for examples see Roberts, RW and Szostak, J.W.I 997. Proc.NatJ.Acad.Sci.USA. 94:12297 - 123202 and PCT Publication No. WO98/31700).
- a DNA library eg of antibodies and derivatives
- translation of the library such that the protein and "immunised" mRN ⁇ s stay on the ribosome
- affinity selection eg by binding to RSP
- mRN ⁇ isolation e.g by reverse translation and subsequent amplification
- reverse translation and subsequent amplification eg by polymerase chain reaction or related technology. Additional rounds of selection and amplification can be coupled as necessary ⁇ to affinity maturation through introduction of somatic mutation in this system or by other methods of affinity maturation as known in the state of the art.
- the antibody or antigen-binding portion thereof according to the invention can be derivatised or linked to another functional molecule.
- the antibody or antigen- binding portion can be functionally linked by chemical coupling, genetic fusion, noncovalenl association or otherwise, to one or more other molecular entities, such as another antibody, a detectable agent, a cytotoxic agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or anli gen-binding portion thereof with another molecule (such as a streptavidin core region or a polyhistidine tag).
- Useful delectable agents with which an antibody or antigen-binding portion thereof may be derivatised include fluorescent compounds.
- Exemplary fluorescent delectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine- ⁇ - napthalenesulfonyl chloride, phycoeiythrin and the like.
- An antibody may also be derivatised wilh delectable enzymes such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When an antibody is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product.
- An antibody may also be dcrivatised with biolin, and detected through indirect measurement of avidin or streptavidin binding.
- the present invention also extends to PEGylatcd antibodies or antibody-binding portion which provide increased half-life and resistance to degradation without a loss in activity (eg. binding affinity) relative to non-PEGylatcd antibody polypeptides.
- the antibody or antibody-binding portion as described herein can be coupled, using methods known in the art, to polymer molecules (preferably PEG) useful for achieving the increased half-life and degradation resistance properties.
- polymer molecules preferably PEG
- Polymer moieties which can be utilised in the invention can be synthetic or naturally occurring and include, but are not limited to, straight or branched chai n polyaikylcnc, polyalkeny lene or polyoxyalkylcne polymeis, or a branched or unbranched polysaccharide such as a horno-or heterapolysaccharidc.
- Preferred examples of synthetic polymers which can be used in the invention include straight or branched chain polyethylene glycol) (PEG), polypropylene glycol), or poly(v ⁇ nyl alcohol) and derivatives or substituted forms thereof.
- Particularly preferred substituted polymers for linkage to antibodies as described herein include substituted PEG, including methoxy(polyethylene glycol).
- Naturally occurring polymer moieties which can be used in addition to or in place ⁇ f PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognised by persons skilled in the art.
- Dcrivatised forms of polymer molecules include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the antibody polypeptides described herein.
- Such derivatives include N- hydraxylsuccinimidc (NIIS) active esters, succinimidyl propionate polymers, and sulfhydryl-sclcctivc reactive agents such as maleimide, vinyl sulfonc, and thiol.
- NIIS N- hydraxylsuccinimidc
- Particularly preferred derivatized polymers include, but are not limited to PEG polymeis having the formulae: PEG-O-CH 2 CH 2 CH 2 -CO 2 -N HS; PEG-O-CH 2 -NHS; PEO-O- CH 2 CH Z -CO 2 -NHS; PKG-S-CH 2 CH 2 -CO-NI IS; PKG-O 2 CNH-CH(R)-CO 2 -NHS; PKG- NHCO-CH 2 CH 2 -CO-NHS; and PEG-O-CH 2 -CO 2 -NHS; where R is (CH 2 ) 4 )NHC0 2 (mPEG), PBG polymers can be linear molecules, or can be branched wherein multiple PEG moieties are present in a single polymer.
- the reactive group (e.g., MAL, NHS, SP ⁇ , VS, or Thiol) may be attached directly to the PRG polymer or may be attached to PEG via a linker molecule.
- the size of polymers useful in the invention can be in the range of between 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, 20 kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa.
- the polymers used in the invention, particularly PEG can be straight chain polymers or may possess a branched conformation.
- the polymer (PEG) molecules useful in the invention can be attached to an antibody or antigen-binding portion thereof using methods which are well known in the art.
- the first step in the attachment of PEG or other polymer moieties to an antibody polypeptide monomer or multimer of the invention is the substitution of the hydroxyl end-groups of the PEG polymer by clectrophiie-containing functional groups.
- PEG polymers are attached to cither cysteine or lysine residues present in the antibody polypeptide monomers or multimers.
- the cysteine and lysine residues can be naturally occurring, or can be engineered into the antibody polypeptide molecule.
- cysteine residues can be recombinantly engineered at the C-terminus of an antibody polypeptide, or residues at specific solvent accessible locations in an antibody polypeptide can be substituted with cysteine or lysine.
- the antibody may be linked to one or more molecules which can increase its half -life in vivo. These molecules arc linked to the antibody at a site on the antibody other than the antigen binding site, so that they do not interfcrc/sterically hinder the antigen-binding site. Typically, such molecules are polypeptides which occur naturally in viv ⁇ and which resist degradation or removal by endogenous mechanisms. It will be obvious to one skilled in the art that fragments or derivatives of such naturally occurring molecules may be used, and that some may not be polypeptides.
- Molecules which increase half life may be selected from the following: (a) proteins from the extracellular matrix, eg. collagen, Jaminin, integrin and fibronectin;
- proteins found in blood eg, fibrin ⁇ -2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, scrum amyloid protein A, hcptaglobin, protein, ubiquitin, utcroglobulin, ⁇ -2 microglobulin, plasminogen, lysozymc, cystatin C, alpha-1-antitrypsin and pancreatic kypsin inhibitor;
- immune serum proteins eg. IgE, IgG, IgM;
- transport proteins eg. rctinol binding protein, ⁇ -1 microglobulin;
- defensins eg. beta-dcfcnsin 1, Neutrophil defcnsins 1, 2 and 3;
- proteins found at the blood brain barrier or in neural tissues eg. melanocortin receptor, myelin, ascorbatc transporter;
- transferrin receptor specific ligand-neuropharmaccutJcai agent fusion proteins see US5977307; brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin- like growth factor 1 (IGF 1) receptor, i ⁇ sulin- ⁇ ke growth factor 2 (IGF 2) receptor, insulin receptor;
- proteins localised to the kidney eg. polyeyslin, type IV collagen, organic anion transporter Kl, Heymann's antigen;
- proteins localised to the lung eg. secretory component (binds IgA);
- proteins localised to the skin eg, keratin
- bone specific proteins such as bone morphogeny proteins (BM Ps) eg. BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-I) and -8 (OP-2);
- BM Ps bone morphogeny proteins
- BMP-2, -4, -5, -6, -7 also referred to as osteogenic protein (OP-I) and -8 (OP-2);
- tumour specific proteins eg. human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsi ⁇ s eg cathepsin B (found in liver and spleen);
- disease-specific proteins eg. antigens expressed only on activated T- cells: including LAG-3 (lymphocyte activation gene), ostcoprotegerin ligand (OPGL) sce Natuie 402, 304-309, 199S); OX40 (a member of the TNF ⁇ receptor family, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human '1' cell leukaemia virus type ⁇ l (HTLV-I)-producing cells - see J. Immunol.
- LAG-3 lymphocyte activation gene
- OPGL ostcoprotegerin ligand
- OX40 a member of the TNF ⁇ receptor family, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human '1' cell leukaemia virus type ⁇ l (HTLV-I)-producing cells - see J. Immunol.
- angiogenic giowth factors including acidic fibroblast growth factor (FGF-I), basic fibroblast growth factor (FGF-2), Vascular endothelial growth factor/vascular permeability factor (VEGF/VPK), transforming growth factor- ⁇ (TGF- ⁇ ), tumor necrosis factor-alpha (TNF ⁇ ), angiogenin, inierlcukin-3 (IL-3), intcrleukin-8 (IL-8), platelet derived endothelial growth factor (PD- BCGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BJ ⁇ (FDGF), fractalkine;
- FGF-I acidic fibroblast growth factor
- FGF-2 basic fibroblast growth factor
- VEGF/VPK Vascular endothelial growth factor/vascular permeability factor
- TGF- ⁇ tumor necrosis factor-alpha
- TNF ⁇ tumor necrosis factor-alpha
- IL-8 inierlcukin-3
- IL-8 platelet derived endot
- stress proteins heat shock proteins
- the invention provides a pharmaceutical composition comprising an effective amount of the chimeric antibody or antigen-binding portion thereof according to the present invention, together with a pharmaceutically acceptable excipient or diluent.
- pharmaceutically acceptable excipient or diluent includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and Lhe like that are physiologically compatible.
- pharmaceutically acceptable carriers include one or more of water, Baline, phosphate buffered saline, dextrose, glycerol, ethan ⁇ l, and the like as well as combinations thereof.
- isotonic agents for example, sugars, polyalcohols such as r ⁇ an ⁇ itol, sorbitol, or sodium chloride in the composition.
- Pharmaceutically acceptable substances such as wetting or minor amounts of auxiliary substances such as wetting or emulsifying agents, preservatives! or buffers.
- effective amount refers to an amount of an antibody or antigen binding portion thereof (including pharmaceutical compositions comprising the antibody or antigen binding portion thereof) sufficient to treat a specified disease of disorder or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder.
- diagnosis refers to an amount of a antibody or antigen binding portion thereof (including pharmaceutical compositions comprising the antibody or antigen binding portion thereof) sufficient to diagnose a specified disease or disorder and/or one or more of its rnamfestutiona, where diagnosis includes identification of the existence of the disease or disorder and/or detection of the extent or severity of the disease or disorder. Often, diagnosis will be carried out with reference to a baseline or background detection level observed for individuals without the disease or disorder. Levels of detection above background or baseline levels (elevated levels of detection) are indicative of the presence and, in some cases, The severity of the condition.
- an individual “in need thereof” may be an individual who has been diagnosed with or previously treated for the disease or disorder to be treated.
- an individual "in need thereof may be an individual who is suspected to have a disease or disorder, is at risk for a disease or disorder, or has previously been diagnosed with the disease or disorder (e.g., diagnosis can include monitoring of the severity (e.g., progression/regression) of the disease or disorder over time and/or in conjunction with therapy).
- the chimeric antibody or antigen-binding portion thereof blocks or stimulates receptors functions or neutralizes active soluble products, such as one or more of the inlerleukins, TN Fa or C5a. More preferably, the active soluble product is human TN Fa.
- the composition may be in a variety of forms, including liquid, semi-solid or solid dosage forms, such as liquid solutions (eg injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes or suppositories.
- lhe composition is in the form of an injectable solution for immunization.
- the administration may be intravenous, subcutaneous, intraperitoneal, intramuscular, transdermal, intrathecal, and intraarterial.
- the dosage form is in the range of from about 0.001 nig to about 10 mg/lfg body weight administered daily, weekly, bi- or tri-wcekly or monthly, mote preferably about 0.05 to about 5 mg/kg body weight weekly.
- composition may also be formulated as a sterile powderlbr the preparation of sterile injectable solutions.
- the active compound may be prepared with a carder that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- a carder that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
- Compatible polymers may be used such as ethylene vinyl acetate, polyanbydrides, polyglycolic acid, collagen, potyorthocsters or polylactic acid.
- composition may also be formulated for oral administration.
- the antibody may be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet.
- composition may also be formulated for rectal administration.
- the antibody r ⁇ ay be administered in order to bind to and identify selected cells in vitro and in vivo, to bind to and destroy selected cells i? ⁇ vlv ⁇ , or in order to penetrate into and destroy selected cells in vivo.
- the antibody may be used as an immunotoxin to deliver a cytotoxic agent eg. a toxin or cliemolherapcutie agent IO a particular cell type such as a tumour cell. Production of irnrnunotoxins would be familiar to persons sltilled in the art.
- Cytotoxic agents commonly used to generate immunotoxins include radioactive isotopes such as 111 In or Y, selenium, libonucleascs, binding domain - deleted truncated microbial toxins such as Pseudomonas exotoxin or Diphtheria toxin, tubulin inhibitors such as calioheamicin (ozagamicin), maytansinoids (including DM-I), auristatins, and taxoids, ribosome inactivating proteins such as ricin, ebulin 1, saporin and gclonin, and prodrugs such as melphalan,
- radioactive isotopes such as 111 In or Y, selenium, libonucleascs, binding domain - deleted truncated microbial toxins such as Pseudomonas exotoxin or Diphtheria toxin
- tubulin inhibitors such as calioheamicin (ozagamicin
- the composition is administered- to a human.
- the present invention also provides Tor Lhe use of the chimeric antibody or antigen-binding portion thereof in a diagnostic application for detecting an antigen associated with a particular disease or disorder,
- the invention provides for the use of the chimeric antibody or antigen-binding portion thereof in a method for diagnosing a subject having an antigen associated with a particular disease or disorder, comprising administering to said subject a diagnostically effective amount of a pharmaceutical composition according to the third aspect.
- a subject is a human.
- the chimeric antibody ⁇ r antigen-binding fragment thereof can be used to detect the presence ⁇ f an antigen, or elevated levels of an antigen (e.g. TNFu) in a biological sample, such as serum or plasma using a convention immunoassay, such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistoehemistry.
- an antigen e.g. TNFu
- a biological sample such as serum or plasma
- a convention immunoassay such as an enzyme linked immunosorbent assay (ELISA), a radioimmunoassay (RIA) or tissue immunohistoehemistry.
- the antigen to which the chimeric antibody or antigen-binding portion thereof binds is peptide, protein, carbohydrate, glycoprotein, lipid or glycolipid in nature, sclccTcd from a tumour-associated antigen including carcinoembryonic antigen, EpC ⁇ M, L ⁇ wis-Y, Lewis- Y/b, PMS ⁇ , CD20, CD30, CD33, CD38, CD52, CD154, EGF-R, Her-2, TRAIL and VEGF receptors, an antigen involved in an immune or tnflanimatory disease or disorder including CD3, CD4, CD25, CD40, CD49d, MHC class I, MHC class II, GM- CSF, inlerferon- ⁇ , IL-I, IL- 12, IL-13, IL-23, TNh'- ⁇ , and IgR, an antigen expressed on a host cell including glycoprotein llb/llla, P-glycoprotcin, purinergic receptors and adh.
- anthrax toxin rattle snake venom and digoxin
- the chimeric antibody acts as an agonist or antagonist or is active Io either deplete (kill or eliminate) undesired cells (eg. a ⁇ ti-CD4) by acting with complement, or killer cells (eg. NK cells) oris active as a cytotoxic agent or to cause Fe-receptor binding by a phagocyte or neutralizes biological activity of its target.
- the anti-human TNF ⁇ chimeric antibody or antigen binding portion thereof according to the invention may also be used in cell culture applications where it is desired to inhibit TNFn activity.
- the present invention also provides a method for treating a disease or disorder characterised by human TNF ⁇ activity in a human subject, comprising administering to the subject in need thereof a pharmaceutical composition according to the present invention in which the chimeric antibody or antigen-binding portion thereof binds TNFre.
- disease or disorder characterised by human TNF ⁇ activity is intended to include diseases or disorders in which the presence of TNF ⁇ in a subject suffering from the disease or disorder has been shown to be or is suspected of being either responsible for the pathophysiology of the disease or disorder or a factor that contributes to the worsening of the disease or disorder. Accordingly, a disease or disorder in which TNF ⁇ activity is detrimental is a disease or disorder in which inhibition of TNFre activity is expected to al leviate symptoms and/or progression of the disease or disorder.
- Such diseases or disorders may be evidenced, for example, by an increase in the concentration of TNF ⁇ in a biological fluid of a subject suffering from the disease or disorder (c.g., an increase in the concentration of TNF ⁇ in serum, plasma, synoviid fluid etc of the subject), which can be detected, for example, using a chimeric antibody of the invention specific for TNF ⁇
- a disease or disorder characterised by human TNF ⁇ activity is intended to include diseases or disorders and other disease or disorder in which the presence of TNF ⁇ in a subject suffering from the disease or disorder has been shown to be, or is suspected of being, cither responsible for the pathophysiology of the disease or disorder or a factor which contributes to a worsening of the disease or disorder.
- the disease or disorder characterised by human TNF ⁇ activity is selected from the group consisting of sepsis, including septic shock, endotoxic shock, gram negative sepsis and toxic shock syndrome; autoimmune disease, including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, psoriasis and gouty arthritis, allergy, multiple sclerosis, autoimmune diabetes, autoimmune uveitis and nephrotic syndrome; infectious disease, including fever and myalgias due to infection and cachexia secondary to infection: graft versus host disease; tumour growth or metastasis; pulmonary disease including adult respiratory distress syndrome, shock lung, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, pulmonary fibrosis and silicosis; inflammatory bowel disease including Crohn's disease and ulcerative colitis; cardiac disease; inflammatory bone disease, hepatitis, coagulation disturbances, burns, reperfusion injury, keloid formation and
- Supplementary active compounds can also be incorporated into lhc composition.
- the ' antibody or antibody-binding fragment may be co-formulalcd with and/or administered simultaneously, separately or sequentially with one or more additional therapeutic agents eg. antibodies that bind to other targets s ⁇ ch as cytokines or cell surface molecules or alternatively one or more chemical agents that inhibit human TNfFa production or activity.
- lhe invention provides a kit comprising a therapeutically effective amount of a chimeric antibody or antigen-binding portion of lhc invention, or a pharmaceutical composition comprising a therapeutically effective amount of a chimeric antibody or antigen-binding portion thereof, together with packaging and instructions for use.
- the instructions for use include instructions for how to effectively administer a therapeutic amount of the chimeric antibody or antigen-binding portion of flic invention,
- V K chain (Accession Number: AAM54057.
- SEQ LD NO: 1 ) of lhe MOG specific marmoset derived antibody was expressed with a human constant region (human IgGI heavy chain C H 1., hinge, Cn2 & C H 3 domains (such as NCBI accession number POl 857) (SEQ ID NO; 2».
- Vr. chain (Accession Number: A AM54058, SEQ ID NO: 3) of the MOG specific marmoset derived antibody was expressed with a human kappa light chain constant region (such as NCBI accession number AAA58989) (SEQ ID NO: 4).
- DNA encoding the light chain (V L - Kappa) amino acid sequence was prepared as described above for tlic heavy chain.
- the supernatant was passed over a HiTrap Protein A column (Amersham Bioseienecs, Cat No; 17-0402-01) three times at a flow rate of 1 mL/min. The column was then washed with 20 mlVt sodium phosphate for 40 niins at I mL/min. The antibody was eluted with 0.1 M citric acid pH 3.5 with fractions collected and immediately neutralised with IM Tris- I ICl ptf 9.0. Antibody samples were then desalted on a PD-10 column ( ⁇ mcrsham Biosciences, Cat No: 17-0851-01). Analysis of the antibody by SDS-P ⁇ GE and size- exclusion HPLC confirmed the correct molecular weight, presence of assembled antibody and the concentration of antibody.
- the pellet and supernatant was diluted into SDS-P ⁇ GE sample buffer (125 ⁇ uM Tris-HCl pH 6.8, 5% SDS, 0.25% bromophenol blue, 25% glycerol).
- SDS-P ⁇ GE sample buffer 125 ⁇ uM Tris-HCl pH 6.8, 5% SDS, 0.25% bromophenol blue, 25% glycerol.
- SIGMA CeILytic M Cell J.ysis Reagent
- rat MOG could be produced using recombinant DNA technology and the ability of AR 138 to bind rat MOG determined in binding assays such as JELIS ⁇ or Biacorc analysis.
- Standard recombinant DNA technology can be used to produce a locally engineered domain antibody by substitution of the CDR2 of an acceptor anti-TNF ⁇ domain antibody (Basran el al. WO 2004/081026; SRQ ID NO: 7; Figure 3) with a CDR2 from a donor New World primate immunoglobulin.
- the CDR2 is identified on the acceptor anti-TNT- ⁇ domain antibody (SASELQS).
- SASELQS acceptor anti-TNT- ⁇ domain antibody
- the domain antibody acceptor sequence is then aligned against a panel of New World primate immunoglobulin sequences. These sequences arc derived from the Ma's night monkey ( ⁇ otus nancymaac) (SEQ !D NOs:.8 - I 8) and from the common marmoset (Callithrix jacchus) (SEQ IT) NOs: 19 - 24 ) ( Figure 4).
- the CDR2 sequences of the New World primate immunoglobulins that differ from that of Lhe acceptor CDR2 sequence can be identified as SASTLQT, DASSLQP, GASTRAT, KVSNRAS, RVSNRAS, KVSTRGF, A ⁇ SNRAS, TSSNLQA, KASTLQS, AASTLQS, YASSLQS, YASFLQG) (Table I).
- BLAST analysis http://www.ncbi.nlm.nih.gov/BLAST/ oil each of these donor New World primate CDR2 sequences is performed to remove sequences that are exact matches for human immunoglobulin sequences. Sequences unique to New World primates were KVSNRAS, RVSNRAS, KVSTRCGP, A ⁇ SNRAS, TSSNLQA, DASSLQP, YASFLQG (Table 1 ).
- Table 1 New World primate CDR2 sequences and their suitability as donor sequences.
- the acceptor CDR2 and the potential donor CDR2s are examined for their predicted immunogenicity in humans by the MHC class U binding prediction program Proprcd (http://www.imleeh.res.in/raghava/prot>rcd) using a 1% threshold value analysis of all alleles. From this analysis the acceptor CDR2, SASELQS, forms part of the peptide, LIYSASF ⁇ LQ, which is predicted to bind MiIC class II encoded by 1 1 alleles (DRBl .0306, DRBl_0307.
- DRB1_O3O8 DRB1_O311, DRBl-0401 , DRB1_O426, DRB1_0806, DRBl_0813, DKBlJ 50 L, DRB I .1502, DRB1_1506).
- the donor CDR2 sequence, KVSNRAS forms part ⁇ f a sequence, LIYK VSNRAS, which is predicted to bind MHC class !l encoded by 9 alleles (DRB 1 _0309, DRB1_O4O2, DRB I _0802, DRB 1_0804, DRB 1. 0806, DRB l_0813, DRB 1 _1301 , DRB IJ 327, DRB I J328).
- the donor CDR2 sequence, ⁇ ASNRAS forms part of a sequence, LlY AASNRA, which is predicted to bind MHC class Il encoded by 6 alleles (DRBl_0402, DRBl_0404, DRBl_040S, DRB1_O423, DIIB1_O813, DRB IJ 506).
- the donor CDR2 sequence, TSSNLQA forms part of a sequence, Ll YTSSNLQA, which is predicted to bind MHC class l[ encoded by 10 alleles (DRBlJMO 1 , DRB l_0402, DRB1_0404, DRB I JWlO 7 DRBl JH23, DRBl J)42(>, DRBl_0813, DRB1J50I , DRBl J502, DRBl J 506).
- the donor CDR2 sequence, KVSTRGP forms part of a sequence LUYKVSTR, which is predicted to bind MUC class II encoded by 8 alleles (DRB1_0309, DRBI_0802, DR.B1J0804, DRB1JJ806, DRB1JJ813, DRB 1 J301, DRB1_1327, DRB1_1328).
- the acceptor CDR2 can be replaced with a donor CDR2 of lower predicted immunogenicity, including KVSNRAS, A ASNRAS, TSSNLQ ⁇ and KVSTRGP.
- the acceptor CDR2 is replaced with the donor CDR2 sequences, generating the locally engineered domain antibodies (SEQ ID No: 25 - 31),
- Examples of recombinant DN ⁇ technology include those described by Winter et al. (US 5,225,539), and include, but is not limited to, techniques such as sile-dirceled mutagenesis and oligo annealing.
- Protein expression of the domain antibodies is then performed in E .colt BL21 (DE3) pLys (Novagcn, Germany) using a suitable vector for expression such as pBT21d(+) (Novagen, Germany), or by other such methods known in the art such as those describe by Basran et al.
- domain antibodies are purified using Protein L (Pierce, USA) chromatography. Following purification the engineered domain antibodies are analysed for retention of TNF ⁇ binding ability by methods known in the art, such as the L929 neutralisation assay or the TNF ⁇ receptor I binding assay.
- affinity maturation could be performed by amino acid substitution of the framework residues surrounding and stabilising CDR2 or by other methods known in the art.(Winter et al. (US 5,225,539); Griffiths et al (US 5,885,793); Rajpal, A. et at (2005) A general method for greatly improving the affinity ot antibodies by using combinatorial libraries, PrM Natl Acad Sci U S A , 102(24) 8466-71 ; Irving R.A. el al. (2001) Rtbosome display and affinity maturation: from antibodies to single V-d ⁇ mains and steps towards cancer therapeutics, Journal of Immunological Methods, 248: 31 -45).
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005904406A AU2005904406A0 (en) | 2005-08-15 | New World Antibodies | |
PCT/AU2006/001166 WO2007019621A1 (en) | 2005-08-15 | 2006-08-15 | Chimeric antibodies with new world primate regions |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1945669A1 true EP1945669A1 (en) | 2008-07-23 |
EP1945669A4 EP1945669A4 (en) | 2009-07-22 |
Family
ID=37757238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06774813A Withdrawn EP1945669A4 (en) | 2005-08-15 | 2006-08-15 | Chimeric antibodies with new world primate regions |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1945669A4 (en) |
JP (1) | JP2009504686A (en) |
KR (1) | KR20080068005A (en) |
CN (2) | CN101287763A (en) |
AU (1) | AU2006281981A1 (en) |
BR (2) | BRPI0614867A2 (en) |
CA (1) | CA2619245A1 (en) |
MX (1) | MX2008002161A (en) |
NO (1) | NO20080800L (en) |
NZ (1) | NZ565904A (en) |
RU (1) | RU2008110058A (en) |
WO (1) | WO2007019621A1 (en) |
ZA (2) | ZA200802246B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | Anti-cd154 antibodies |
EA017417B1 (en) | 2006-02-01 | 2012-12-28 | Сефалон Астралия Пти Лтд. | DOMAIN ANTIBODY CONSTRUCT WHICH BINDS TO HUMAN TNF-α AND USE THEREOF |
NZ580245A (en) * | 2007-03-22 | 2012-01-12 | Biogen Idec Inc | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
US20110319597A1 (en) * | 2008-08-14 | 2011-12-29 | Caphalon Australia Pty. Ltd. | Variant domain antibodies |
RU2505312C2 (en) * | 2010-08-06 | 2014-01-27 | Олег Ильич Эпштейн | Combined therapeutic agent for treating various types of influenza |
RU2521392C2 (en) * | 2010-08-06 | 2014-06-27 | Олег Ильич Эпштейн | Combined drug for treating viral infections and method of treating viral infections |
RU2577299C2 (en) * | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Method for treating infectious diseases and complex medication for treatment of infectious diseases |
RU2516931C2 (en) * | 2010-08-06 | 2014-05-20 | Олег Ильич Эпштейн | Method and composition for preventing hiv infection, preventing and treating hiv-caused or hiv-associated diseases, including aids |
RU2535034C2 (en) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Medication and method of preventing hiv infection, prevention and treatment of hiv-induced or hiv-associated diseases, including aids |
RU2535033C2 (en) * | 2010-08-06 | 2014-12-10 | Олег Ильич Эпштейн | Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids |
RU2502521C2 (en) * | 2010-08-06 | 2013-12-27 | Олег Ильич Эпштейн | Combined drug for treating bacterial infections and method of treating bacterial infections |
RU2519862C2 (en) * | 2010-08-06 | 2014-06-20 | Олег Ильич Эпштейн | Complex medication and method of prevention and treatment of infectious viral diseases |
RU2517085C2 (en) * | 2010-08-06 | 2014-05-27 | Олег Ильич Эпштейн | Complex medication and method of preventing hiv infection, prevention and treatment of hiv-induced and hiv-associated diseases, including aids |
RU2579262C1 (en) * | 2014-10-02 | 2016-04-10 | Мапикс Эс.Эй.Ар.Эл. | Medicinal agent for treating infectious diseases |
CL2015002152A1 (en) * | 2015-07-31 | 2016-06-03 | Pontificia Universidad Católica De Chile | Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993002108A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO2002033042A2 (en) * | 2000-10-17 | 2002-04-25 | The Regents Of The University Of California | Recombinant antibody fragments as autoantibody antagonists |
US20030143682A1 (en) * | 2000-11-07 | 2003-07-31 | Nicolaides Nicholas C. | Antibodies and methods for generating genetically altered antibodies with high affinity |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1692174A2 (en) * | 2003-11-07 | 2006-08-23 | Amgen Inc. | Monkey immunoglobulin sequences |
-
2006
- 2006-08-15 NZ NZ565904A patent/NZ565904A/en not_active IP Right Cessation
- 2006-08-15 CN CNA2006800382565A patent/CN101287763A/en active Pending
- 2006-08-15 BR BRPI0614867-0A patent/BRPI0614867A2/en not_active IP Right Cessation
- 2006-08-15 RU RU2008110058/13A patent/RU2008110058A/en not_active Application Discontinuation
- 2006-08-15 AU AU2006281981A patent/AU2006281981A1/en not_active Abandoned
- 2006-08-15 KR KR1020087006270A patent/KR20080068005A/en not_active Application Discontinuation
- 2006-08-15 WO PCT/AU2006/001166 patent/WO2007019621A1/en active Application Filing
- 2006-08-15 EP EP06774813A patent/EP1945669A4/en not_active Withdrawn
- 2006-08-15 CA CA002619245A patent/CA2619245A1/en not_active Abandoned
- 2006-08-15 BR BRPI0614430-6A patent/BRPI0614430A2/en not_active IP Right Cessation
- 2006-08-15 ZA ZA200802246A patent/ZA200802246B/en unknown
- 2006-08-15 CN CNA2006800381577A patent/CN101287762A/en active Pending
- 2006-08-15 MX MX2008002161A patent/MX2008002161A/en not_active Application Discontinuation
- 2006-08-15 ZA ZA200802247A patent/ZA200802247B/en unknown
- 2006-08-15 JP JP2008526323A patent/JP2009504686A/en active Pending
-
2008
- 2008-02-14 NO NO20080800A patent/NO20080800L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993002108A1 (en) * | 1991-07-25 | 1993-02-04 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
WO2002033042A2 (en) * | 2000-10-17 | 2002-04-25 | The Regents Of The University Of California | Recombinant antibody fragments as autoantibody antagonists |
US20030143682A1 (en) * | 2000-11-07 | 2003-07-31 | Nicolaides Nicholas C. | Antibodies and methods for generating genetically altered antibodies with high affinity |
WO2004003019A2 (en) * | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
Non-Patent Citations (6)
Title |
---|
FOOTE J ET AL: "Antibody framework residues affecting the conformation of the hypervariable loops" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 224, no. 2, 20 March 1992 (1992-03-20), pages 487-499, XP024011188 ISSN: 0022-2836 [retrieved on 1992-03-20] * |
HOLT L J ET AL: "Domain antibodies: proteins for therapy" TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484-490, XP004467495 ISSN: 0167-7799 * |
REITER Y ET AL: "An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 290, no. 3, 1 January 1999 (1999-01-01), pages 685-698, XP004461990 ISSN: 0022-2836 * |
See also references of WO2007019621A1 * |
SPEIDEL M T ET AL: "Detection of human and marmoset immunoglobulin heavy chain by a polyclonal antiserum to a marmoset immunoglobulin-related T cell product" EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, S.KARGER, BASEL, CH, vol. 6, no. 4, 1 January 1989 (1989-01-01), pages 245-250, XP009116561 ISSN: 0254-9670 * |
VON BUDINGEN HANS-CHRISTIAN ET AL: "Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus" IMMUNOGENETICS, vol. 53, no. 7, September 2001 (2001-09), pages 557-563, XP002527012 ISSN: 0093-7711 * |
Also Published As
Publication number | Publication date |
---|---|
NZ565904A (en) | 2012-02-24 |
AU2006281981A1 (en) | 2007-02-22 |
NO20080800L (en) | 2008-05-09 |
EP1945669A4 (en) | 2009-07-22 |
ZA200802246B (en) | 2009-09-30 |
CN101287762A (en) | 2008-10-15 |
BRPI0614867A2 (en) | 2012-01-31 |
WO2007019621A1 (en) | 2007-02-22 |
BRPI0614430A2 (en) | 2011-03-29 |
CN101287763A (en) | 2008-10-15 |
RU2008110058A (en) | 2009-09-27 |
JP2009504686A (en) | 2009-02-05 |
ZA200802247B (en) | 2009-08-26 |
MX2008002161A (en) | 2008-04-22 |
CA2619245A1 (en) | 2007-02-22 |
KR20080068005A (en) | 2008-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007019621A1 (en) | Chimeric antibodies with new world primate regions | |
US20080095767A1 (en) | Engineered antibodies with new world primate framework regions | |
US20080255343A1 (en) | Chimeric antibodies | |
JP5030782B2 (en) | Single domain antibody against TNFR1 and method of use thereof | |
AU2007211829B2 (en) | Domain antibody construct | |
CN107849136B (en) | anti-TfR antibodies and their use in the treatment of proliferative and inflammatory diseases | |
AU2006326937B2 (en) | Anti-inflammatory dAb | |
TW200848427A (en) | Ligand | |
AU2008219666A1 (en) | Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases | |
JP2009525031A5 (en) | ||
MX2008002162A (en) | Engineered antibodies with new world primate framework regions | |
NZ569405A (en) | Anti-inflammatory domain antibody binding to TNF-alpha |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080317 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/46 20060101ALI20090528BHEP Ipc: A61K 39/395 20060101ALI20090528BHEP Ipc: C07K 16/18 20060101AFI20070420BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090618 |
|
17Q | First examination report despatched |
Effective date: 20091006 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CEPHALON AUSTRALIA PTY LTD |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130301 |